PAM50 HER2-E Subtype Predicts Response Following Dual HER2 Blockade

Share this content:
PAM50 HER2-enriched subtype predicts pathologic complete response following neoadjuvant lapatinib and trastuzumab.
PAM50 HER2-enriched subtype predicts pathologic complete response following neoadjuvant lapatinib and trastuzumab.

PAM50 HER2-enriched subtype predicts pathologic complete response following neoadjuvant lapatinib and trastuzumab with or without endocrine therapy in patients with human epidermal growth factor receptor 2-positive (HER2+) breast cancer, particularly those with HER2+, hormone receptor (HR)-positive disease, according to findings that will be presented at the 2016 San Antonio Breast Cancer Symposium.1

Previous studies have demonstrated that 6% to 36% of patients with HER2+ breast cancer achieve pathologic complete response with neoadjuvant dual HER2 blockade without chemotherapy. It is unclear, however, which subpopulations derive the maximum benefit from dual anti-HER2 therapies without chemotherapy.

Researchers therefore prospectively evaluated the ability of the PAM50 HER2-enriched intrinsic subtype to predict pathologic complete response in the breast following 18 weeks of neoadjuvant dual HER2 blockade.

For the multicenter, open-label, phase 2, translational research PAMELA study (ClinicalTrials.gov Identifier: NCT01973660), investigators enrolled 151 patients with HER2+ breast cancer to receive 18 weeks of neoadjuvant treatment with lapatinib and trastuzumab. Of those, 60.2% were postmenopausal, 63.5% had negative axillary lymph nodes, and 66.9% had the PAM50 HER2-enriched subtype. Patients with HR-positive disease also received letrozole if postmenopausal or tamoxifen if premenopausal.

Results showed that 30.5% of patients overall, 18.2% with HR-positive disease, and 43.2% with HR-negative disease achieved a pathologic complete response. Researchers found that 40.6% of patients with the HER2-enriched subtype achieved a pathologic complete response compared with 10.0% of those with non-HER2-enriched subtypes (P < .0001).

Among patients with HR-positive disease, 31.6% of patients with the HER2-enriched subtype had a pathologic complete response, vs 5.3% of those with non-HER2-enriched subtypes (P = .006). Among patients with HR-negative disease, 46.0% and 27.3% of those with and without the HER2-enriched subtype achieved a pathologic complete response, respectively (P = .331).

RELATED: Does Dose-dense Chemotherapy Improve Outcomes for Patients With High-risk Early Breast Cancer?

The study demonstrated that the HER2-enriched subtype was predictive of pathologic complete response regardless of HR status in women with HER2-positive breast cancer undergoing adjuvant lapatinib and trastuzumab with or without endocrine therapy.

Reference

  1. Prat Aparicio A, Cortes Castan J, Pare L, et al. PAM50 intrinsic subtype as a predictor of pathological complete response following neoadjuvant dual HER2 blockade without chemotherapy in HER2-positive breast cancer: First results of the PAMELA clinical trial. Paper presented at: 2016 San Antonio Breast Cancer Symposium (SABCS); December 6-10, 2016; San Antonio, TX.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs